Biotechnology · Bala Cynwyd, Pennsylvania, United States
$4.05
-4.26% (-$0.18)2026-08-24
Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($167K, 1 buy vs 0 sales)
Net Income-$32.8M
EPS$-1.50
Market Cap$420.7M
Price Performance
Historical data including institutional events
Company Profile
C
Carole Ben-Maimon
CEO & Executive Director
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreichâs ataxia, a rare, progressive and fatal disease.
The company is based in Bala Cynwyd, Pennsylvania.
